The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Flomoxef     (6R,7R)-7-[2- (difluoromethylsulfanyl) ethan...

Synonyms: Flomoxefo, Flomoxefum, FMOX, Flomoxef (INN), CHEMBL15413, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of S 6315


High impact information on S 6315

  • Its activity is due to a high affinity of the penicillin-binding protein 2' in MRSA, an affinity which was approximately 1,050 times as high as that for flomoxef [6].
  • FK037 was less resistant than flomoxef to hydrolysis by beta-lactamase group 2e derived from B. fragilis GAI 0558 and GAI 10150 [1].
  • The mixed infection rat pouch model was treated with either flomoxef (susceptible to hydrolysis by the beta-lactamase produced by B. fragilis), or cefmetazole (relatively resistant to hydrolysis) [7].
  • The susceptibility of 113 strains of pathogenic Nocardia, N. asteroides, N. farcinica, N. nova, N. brasiliensis and N. otitidiscaviarum to a new oxacephem antibiotic flomoxef was determined by an agar dilution method in comparison with those of 13 other cephalosporins [5].
  • We used the antimicrobial agents, flomoxef (FMOX) and gentamicin (GM), to investigate the kinetics of ET released from in-vitro-cultured Escherichia coli and to examine the ET effect on tumor necrosis factor (TNF) production by macrophages [8].

Chemical compound and disease context of S 6315


Biological context of S 6315


Anatomical context of S 6315


Associations of S 6315 with other chemical compounds


Gene context of S 6315

  • The in vitro frequency of spontaneous mutant cells highly resistant to FK037 in MRSA was lower than that to cefpirome and flomoxef [24].
  • Moreover, the capacity to induce PBP 2a was lower for FK037 than that of cefpirome but higher than that of flomoxef [24].
  • The efficacy of a new protocol consisting of a prophylactic antibiotic regimen of peri- and postoperative intravenous administration of flomoxef and irrigation of the operative field with saline containing gentamicin was assessed by comparing infection rates in two consecutive series of patients who underwent neurosurgical procedures [16].

Analytical, diagnostic and therapeutic context of S 6315


  1. In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria. Kato, N., Kato, H., Tanaka, Y., Bando, K., Watanabe, K., Ueno, K. Antimicrob. Agents Chemother. (1993) [Pubmed]
  2. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Ishii, Y., Ohno, A., Taguchi, H., Imajo, S., Ishiguro, M., Matsuzawa, H. Antimicrob. Agents Chemother. (1995) [Pubmed]
  3. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Hanaki, H., Akagi, H., Masaru, Y., Otani, T., Hyodo, A., Hiramatsu, K. Antimicrob. Agents Chemother. (1995) [Pubmed]
  4. In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum. Iwahi, T., Okonogi, K., Yamazaki, T., Shiki, S., Kondo, M., Miyake, A., Imada, A. Antimicrob. Agents Chemother. (1992) [Pubmed]
  5. In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. Yazawa, K., Mikami, Y., Uno, J., Otozai, K., Arai, T. J. Antimicrob. Chemother. (1989) [Pubmed]
  6. In vitro and in vivo antibacterial activities of OPC-20011, a novel parenteral broad-spectrum 2-oxaisocephem antibiotic. Matsumoto, M., Tamaoka, H., Ishikawa, H., Kikuchi, M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  7. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections. Ajiki, Y., Koga, T., Ohya, S., Takenouchi, T., Yasuda, H., Watanabe, K., Ueno, K. J. Antimicrob. Chemother. (1991) [Pubmed]
  8. Relevance of antimicrobial agent-induced endotoxin release from in vitro cultured Escherichia coli and in vivo experimental infection with Gram-negative bacilli. Tsumura, H., Hiyama, E., Kodama, T., Sueda, T., Yokoyama, T. Int. J. Antimicrob. Agents (2003) [Pubmed]
  9. In vitro activity of flomoxef in comparison to other cephalosporins. Simon, C., Simon, M., Plieth, C. Infection (1988) [Pubmed]
  10. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Bauernfeind, A., Schweighart, S., Eberlein, E., Jungwirth, R. Infection (1991) [Pubmed]
  11. Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency. Andrassy, K., Koderisch, J., Gorges, K., Sonntag, H., Hirauchi, K. Infection (1991) [Pubmed]
  12. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Inoue, K., Inoue, E., Mitsuhashi, S. Chemotherapy. (1995) [Pubmed]
  13. Pharmacokinetics of flomoxef in mucosal tissue of the middle ear and mastoid following intravenous administration in humans. Saito, H., Kimura, T., Takeda, T., Kishimoto, S., Oguma, T., Shimamura, K. Chemotherapy. (1990) [Pubmed]
  14. Effect of flomoxef on blood coagulation and alcohol metabolism. Uchida, K., Matsubara, T. Infection (1991) [Pubmed]
  15. Effect of flomoxef on human platelet aggregation. Cazzola, M., Matera, M.G., Gusmitta, A., Rossi, F. Eur. J. Clin. Pharmacol. (1991) [Pubmed]
  16. Perioperative antimicrobial prophylaxis in neurosurgery: clinical trial of systemic flomoxef administration and saline containing gentamicin for irrigation. Yamamoto, M., Jimbo, M., Ide, M., Tanaka, N., Umebara, Y., Hagiwara, S. Neurol. Med. Chir. (Tokyo) (1996) [Pubmed]
  17. Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. Hayashi, J., Kawarada, Y., Isaji, S., Yokoi, H., Higashiguchi, T. Pancreas (1996) [Pubmed]
  18. Studies on the antibiotic transfer into the bile of canines with different bile duct pressures. Nakata, K., Kinoshita, H., Kubo, S., Igimi, H., Yamamoto, S. Chemotherapy. (1992) [Pubmed]
  19. The meaning of the development of flomoxef and clinical experience in Japan. Ito, M., Ishigami, T. Infection (1991) [Pubmed]
  20. Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus. Murakami, K., Nomura, K., Doi, M., Yoshida, T. Antimicrob. Agents Chemother. (1987) [Pubmed]
  21. Effect of water mobility on drug hydrolysis rates in gelatin gels. Yoshioka, S., Aso, Y., Terao, T. Pharm. Res. (1992) [Pubmed]
  22. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin. Nishino, T., Otsuki, M., Hatano, K., Nishihara, Y. Chemotherapy. (1994) [Pubmed]
  23. The in vitro activity of flomoxef compared to four other cephalosporins and imipenem. Shah, P.M., Knothe, H. Infection (1991) [Pubmed]
  24. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci. Mine, Y., Watanabe, Y., Sakamoto, H., Hatano, K., Kuno, K., Kamimura, T., Tawara, S., Matsumoto, Y., Matsumoto, F., Kuwahara, S. J. Antibiot. (1993) [Pubmed]
  25. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. Lee, C.H., Su, L.H., Tang, Y.F., Liu, J.W. J. Antimicrob. Chemother. (2006) [Pubmed]
  26. Effects of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement. Takechi, M., Miyamoto, Y., Ishikawa, K., Nagayama, M., Kon, M., Asaoka, K., Suzuki, K. J. Biomed. Mater. Res. (1998) [Pubmed]
  27. Diurnal variation in the biliary excretion of flomoxef in patients with percutaneous transhepatic biliary drainage. Hishikawa, S., Kobayashi, E., Sugimoto , K., Miyata, M., Fujimura, A. British journal of clinical pharmacology. (2001) [Pubmed]
  28. Continuous monitoring of unbound flomoxef levels in rat blood using microdialysis and its new pharmacokinetic analysis. Saisho, Y., Umeda, T. Chem. Pharm. Bull. (1991) [Pubmed]
  29. Dosing-time-dependent variation in biliary excretion of flomoxef in rats. Hishikawa, S., Sugimoto, K., Kobayashi, E., Kumagai, Y., Fujimura, A. Chronobiol. Int. (2003) [Pubmed]
WikiGenes - Universities